Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.48 |
| ▸ | FLT3 | P36888 | 3/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5576425 | 0.82 | BRAF (0.60) | RAF1MAPK14FLT3 | |
| SCHEMBL5573475 | 0.80 | RAF1 (0.68) | RAF1MAPK14FLT3NPC1RAB9A | |
| SCHEMBL938751 | 0.79 | RAF1 (0.80) | RAF1MAPK14FLT3MAPK13MAPK12 | |
| SCHEMBL18580523 | 0.75 | SMN1; SMN2 (0.57) | CTSDNPC1MAPTRAB9ACYP1A2 | |
| SCHEMBL5575729 | 0.74 | RAF1 (0.54) | RAF1MAPK14FLT3EPHX2MAPK13 | |
| SCHEMBL668575 | 0.74 | RAF1 (0.81) | RAF1MAPK14FLT3MAPK13MAPK12 | |
| SCHEMBL7814153 | 0.73 | RAF1 (0.53) | RAF1MAPK14FLT3KDR | |
| SCHEMBL938678 | 0.73 | RAF1 (0.65) | RAF1MAPK14FLT3EPHX2MAPK13 | |
| SCHEMBL667449 | 0.71 | RAF1 (0.80) | RAF1MAPK14FLT3MAPK13MAPK12 | |
| SCHEMBL11130435 | 0.71 | SMN1; SMN2 (0.61) | CTSDNPC1MAPTRAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | claimed |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2012-02-23 | — | — | US | claimed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2012-02-23 | — | — | US | disclosed |
| EP-1041982-A4 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1041982-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | RAF1 155/4885MAPK14 31/4885FLT3 167/4885 |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | RAF1 155/4885MAPK14 31/4885FLT3 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.